Fundraising Fox
Crossbow Therapeutics
Cambridge, US · Founded 2021 · Delaware corporation · 41 employees on LinkedIn · 8 known investors
Find your way into Crossbow Therapeutics
Sign up to see every warm intro you have to Crossbow Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Crossbow Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.
Founders & leadership
Board
Investors · 8
How we know: MPM BioImpact's portfolio page · a partner's Signal profile · board seat on SEC Form D · press coverage · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements$144.8M disclosed across 3 rounds · 2023–2026
- $77MSeries BMar 2026Source ↗
▶$30.3MraisedSep 2025 · 17 investors · BiotechnologyRule 506(b)
- Alexander NolteExecutive Officer
- Alexandra CantleyDirector
- Dmitri WiederschainExecutive Officer
- Sakae AsanumaDirector
- Charles BaumDirector
- Briggs MorrisonExecutive Officer, Director, Promoter
- Irena MelnikovaDirector
- Alon LazarusDirector
- Todd FoleyDirector
- Offering amount
- $80M
- Amount sold
- $30.3M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$37.6MraisedApr 2023 · 15 investors · BiotechnologyRule 506(b)
- Irena MelnikovaDirector
- Todd FoleyDirector
- Briggs MorrisonExecutive Officer, Director
- Alexandra CantleyDirector
- Geraldine PaulusExecutive Officer
- Offering amount
- $80M
- Amount sold
- $37.6M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Crossbow Therapeutics went on to found or lead other companies.
Related companies · 3
Companies working in the same space as Crossbow Therapeutics.
In the news
Frequently asked questions
- What does Crossbow Therapeutics do?
- Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.
- Who are Crossbow Therapeutics's investors?
- Crossbow Therapeutics's investors include Lifelink, MPM BioImpact, Pfizer Venture Investments, Biotechnology Value Fund, Mirae Asset Venture Investment, Pfizer Ventures, Polaris Partners, Taiho Ventures, LLC.
- How much funding has Crossbow Therapeutics raised?
- Crossbow Therapeutics has disclosed $144.8M raised across 3 rounds.
- Where is Crossbow Therapeutics headquartered?
- Crossbow Therapeutics is headquartered in Cambridge, US.